 |
 |
|
 |
||
 |
 |
 |
"Think of genetic research as language. We have identified the words; now we are constructing the dictionary and learning the rules of grammar. Our task is to continue assembling the dictionary and perhaps the construction of a few grammatically accurate sentences. The goal is to eventually add new chapters to the novel of life." Antonio Giordano |
 |
 |
|
     |
ADMINISTRATION |
||||
President and Chairman of the Board |
SCIENTIFIC ADVISORY BOARD |
|||||
SHRO Law Firms |
Public Relations and Communications |
|||||
 |
|
ANTONIO GIORDANO, M.D., Ph.D.
At 26, while a post-doctoral fellow at Cold Spring Harbor Laboratory in New York, Dr. Giordano discovered the protein cyclin A, a substance that regulates growth in the cell cycle. At Temple University’s Fels Cancer Institute in the 1990’s, he discovered Rb2. His subsequent research has shown that the protein expression of the tumor suppressing gene Rb2/p130 is active in lung, endometrial, brain, breast, liver and ovarian cancers. He also discovered the cyclin-dependent kinases CDK9 and CDK10, genetic substances that must be activated to guarantee proper progression through the cell cycle. Research has revealed that CDK9 also plays a critical role in cell differentiation, particularly in muscles, HIV transcription, and the inception of tumors. A native of Naples, Italy, Dr. Giordano earned his medical degree summa cum laude from the University of Naples and his doctorate in Pathology summa cum laude from the University of Trieste Medical School. He was a post-doctoral fellow in the Department of Microbiology and Immunology at New York Medical College in Valhalla (N.Y.) as well as a post-doctoral fellow at Cold Spring Harbor Laboratory (N.Y). Since 1992, Dr. Giordano has been awarded 20 patents for his research. He has published 310 papers on his work in the fields of cell cycles, gene therapy and the genetics of cancer and serves on a number of editorial boards including Cancer Therapy, Current Cancer Therapy Reviews, International Journal of Oncology, The Open Cancer Journal, and The Women’s Oncology Review (Editor-USA). In the past ten years he has been an invited lecturer at over 150 scientific meetings held within the U.S. and abroad. His work has been funded by the United States Department of Defense, Congressionally Directed Medical Program-Breast Cancer Research Program, the National Institutes of Health, The National Cancer Institute and the Commonwealth of Pennsylvania, Department of Health, Cancer Research Program, Dr. Giordano is a member of the American Association for Cancer Research, American Association for the Advancement of Science, The New York Academy of Sciences, The International Society for the Study of Comparative Oncology, and The Italian Tumor Society In the past three years, Dr. Giordano’s work has been profiled in Philadelphia Magazine, Philadelphia Business Journal, and Science. Dr. Giordano and his wife, Mina Massaro Giordano, M.D., live in Radnor, PA with their three children. |
An internationally recognized researcher specializing in the genetics of cancer and gene therapy, Antonio Giordano, M.D., Ph.D., 46, is the President and Chairman of the Board of the Sbarro Health Research Organization, Director of the Sbarro Institute for Cancer Research and Molecular Medicine and Director of the Center of Biotechnology at Temple University's College of Science and Technology. Dr. Giordano also serves as the Director of the Scientific Advisory Committee for the Human Health Foundation (HHF), an Italian charity for basic medical research that he founded with the President of the Banca Popolare di Spoleto, Giovannino Antonini. In addition, he is the President of the Scientific Advisory Board for the Centro di Ricerche Oncologiche di Mercolgiano (CROM), in Mercogliano Italy. Dr. Giordano is a professor at Temple University and 'Chiara fama' professor in Pathology at the University of Siena in Siena, Italy. |
TOP | CONTACT | SALUTE-HEALTH | DONATE | LINKS |
 © Copyright 2003 - 2008, Sbarro Health Research Organization,All rights reserved. |